Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories


Schroders shifts Carrick stake at discount
Schroder UK Public Private Trust, the rebranded fund previously led by Neil Woodford, has sold its shareholding in Carrick Therapeutics at a discount.
Paragon passes acquisition exam
University of British Columbia spinout Paragon Testing Enterprises has agreed to an acquisition by Prometric Canada Testing Services.
Vaccitech shoots for US IPO
Oxford spinout Vaccitech, which developed the technology underlying the university’s covid vaccine, has filed for an offering on the Nasdaq Global Market.
Dysonics takes a dive into Google
UC Davis spinout Dysonics was acquired by Google last year, it has emerged.
Coursera graduates to public markets in $519m IPO
The online learning platform developer spun out of Stanford University priced its shares at the top of their range.
Achilles ascends to Nasdaq
Achilles Therapeutics has raised more than $175m in its initial public offering on the Nasdaq Global Select Market.
Lilium lands on $3.3bn reverse merger
The vertical take-off and landing jet developer, an Unternehmertum spinout, is joining forces with the Nasdaq-listed Qell Acquisition Corp.
Lava breaks through to public markets
Lava Therapeutics, which is developing cancer treatments based on research at Amsterdam University Medical Centers, floated in a $101m offering.

Other News

Multiphoton Optics eyes exit
Heidelberg Instruments Mikrotechnik has acquired the Fraunhofer spinout for an undisclosed sum.
Akoya acts to file for $115m IPO
The tissue analysis device maker, a spinout from Stanford University, has selected the Nasdaq Global Select Market for its initial public offering.
Stirling Ultracold warms to BioLife
BioLife Solutions will issue more than 6.6 million shares to acquire Ohio University-affiliated Stirling Ultracold in an all-stock transaction.
Recursion takes steps toward IPO
The University of Utah spinout is looking to float on the Nasdaq Global Select Market and has filed with a $100m placeholder amount.
Enechange snaps up Smap Energy
Cambridge Enterprise is celebrating another win with the acquisition of Smap Energy by Enechange.
Renovacor reaches reverse merger deal
The gene therapy developer focused on cardiovascular and central nervous system diseases will merge with Chardan Healthcare Acquisition 2 Corp to list on NYSE.

Editor's Picks

Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg